In the United States, salvage therapy patients account for between 50,000 and 80,000 of the 1.1 million people thought to be HIV positive.
Because the market for salvage therapy is just a fraction of the overall AIDS treatment market, pharmaceutical companies sell their last-chance drugs for a higher price than so-called first line treatments.
When Merck was contacted about the price-gouging accusations, a media representative referred AFP to a statement issued by the company two weeks ago.
In the statement, Merck said AHF's accusations were false, and insisted it had priced Isentress "responsibly ... after consultation with respected leaders in the HIV community."
Source-AFP
RAS